In the 1970s it was proposed that inhibition of angiogenesis could starve the tumor of essential nutrients and oxygen2, leading many pharmaceutical companies to develop drugs targeting pro-angiogenic factors such as vascular endothelial growth factor (VEGF). The gene discussed is VEGFA; the disease is neoplasm.